Search filters

Sale of Mestex AG to Grünenthal

The previous owners of Mestex AG, a Swiss biotech company developing, sold their shares and stock options to the pharmaceutical company Grünenthal

Majority stake of STIMIT sold to Dräger

The Swiss-based start-up medical technology company STIMIT AG was founded in 2018...

CITIC becomes largest shareholder in MedAlliance

Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.

Sale of NBE-Therapeutics to Boehringer Ingelheim for EUR 1.18bn

Boehringer Ingelheim and the shareholders of NBE-Therapeutics have signed a share purchase agreement with a total transaction value of EUR 1.18bn which also includes contingent clinical and regulatory milestones.

Synendos raises CHF 20m in a Series A financing round

Synendos Therapeutics AG (“Synendos”), a Swiss a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for...

Polyneuron extends Series A Financing to CHF 36.5m

Polyneuron Pharmaceuticals AG extended its Series A by CHF 14m bringing the total to CHF 36.5m. Polyneuron is a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients affected by...

AFINUM acquires Threema

AFINUM has acquired Threema GmbH, Freienbach (CH), the Swiss developer and provider of the leading European secure messenger solution for professional and personal communication. As part of this transaction, the three founders...

T3 Pharma closes 25M CHF financing round

T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, closed its third financing round, raising over 25M CHF. The financing was co-led by existing...

Polares Medical closes a USD40M financing for pilot clinical studies

Polares Medical SA, in Lausanne, a clinical stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR),...

Azafaros expands executive management team and operations

Azafaros B.V., headquartered in Leiden, The Netherlands, has recently incorporated a Swiss subsidiary in the pharma hub of Basel to strengthen its research and development operations. In addition, three experienced industry...

You are currently offline. Some pages or content may fail to load.